WEST Search History

Hide Items		

DATE: Monday, May 16, 2005

Hide?	Set Nam	e Query	Hit Count
	DB=PG	PB; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
	L3	thioredoxin reductase same aureus and crystal\$9	6
	DB = USI	PT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YE	S; OP=ADJ
	L2	thioredoxin reductase same aureus and crystal\$9	3
	L1	thioredoxin reductase same aureus same crystal\$9	1

END OF SEARCH HISTORY

Hit List

Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: US 6767536 B1

L2: Entry 1 of 3

File: USPT

Jul 27, 2004

US-PAT-NO: 6767536

DOCUMENT-IDENTIFIER: US 6767536 B1

** See image for Certificate of Correction **

TITLE: Recombinant Staphylococcus thioredoxin reductase and inhibitors thereof

useful as antimicrobial agents

DATE-ISSUED: July 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aharonowitz; Yair	Hod Hasharon			IL
Borovok; Ilya	Ariel			IL
Cohen; Gerald	Raanana .			IL
Uziel; Orit	Kfar-Saba			IL
Katz; Leonard	Oakland	CA		

US-CL-CURRENT: 424/93.42; 424/139.1, 424/165.1, 424/185.1, 424/237.1, 424/243.1, 424/94.1, 435/191, 435/252.3, 435/36, 435/471, 435/7.33, 435/7.7, 435/91.1, 435/91.5, 435/91.51

ABSTRACT:

Isolated and purified Staphylococcus thioredoxin reductases (TrxB) are provided. Polynucleotides encoding the TrxBs, vectors and host cells containing such polynucleotides are also provided. In addition, antibodies reactive with the TrxBs are provided, as are methods of isolating the TrxBs, as well as methods for producing recombinant TrxBs, using TrxBs for screening compounds for TrxB-modulating activity, and detecting Staphylococcus in a test sample.

8 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full	Title	Citation	Frent	Review	Classification	Date	Reference		Claims	KAMC	Draw D
		10000			9						

2. Document ID: US 6559294 B1

L2: Entry 2 of 3

File: USPT

May 6, 2003

Record List Display Page 2 of 5

US-PAT-NO: 6559294

DOCUMENT-IDENTIFIER: US 6559294 B1

** See image for Certificate of Correction **

TITLE: Chlamydia pneumoniae polynucleotides and uses thereof

DATE-ISSUED: May 6, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Griffais; Remy Momtrouge FR Hoiseth; Susan K. Fairport NY Zagursky; Robert John Victor NY Metcalf; Benjamin J. Rochester NY Peek; Joel A. Pittsford NY Sankaran; Banumathi Penfield NY Fletcher; Leah Diane Geneseo NY

US-CL-CURRENT: 536/23.1; 435/320.1, 435/69.1, 435/70.1, 536/24.1

ABSTRACT:

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular Chlamydia pneumoniae, infections.

13 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference Claims KMC Draw De

Document ID: US 20030166843 A1, WO 200177309 A2, AU 200149786 A

L2: Entry 3 of 3

File: DWPI

Sep 4, 2003

DERWENT-ACC-NO: 2002-034237

DERWENT-WEEK: 200359

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Crystallizing Staphylococcus aureus thioredoxin reductase molecule or

Record List Display Page 3 of 5

molecular complex by preparing purified thioredoxin reductase and crystallizing from solution comprising dimethyl sulfoxide and sodium formate

INVENTOR: BENSON, T E

PRIORITY-DATA: 2000US-195055P (April 6, 2000), 2001US-0825212 (April 3, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030166843 A1	September 4, 2003		000	C07K001/00
WO 200177309 A2	October 18, 2001	E	147	C12N009/02
AU 200149786 A	October 23, 2001		000	C12N009/02

INT-CL (IPC): <u>C07 K 1/00</u>; <u>C07 K 14/00</u>; <u>C07 K 17/00</u>; <u>C12 N 9/02</u>; <u>C12 Q 1/26</u>; <u>G06 F</u> 17/50

ABSTRACTED-PUB-NO: WO 200177309A

BASIC-ABSTRACT:

NOVELTY - Crystallizing (M1) Staphylococcus <u>aureus thioredoxin reductase</u> molecule or molecular complex involves preparing purified S.aureus <u>thioredoxin reductase</u> at a concentration of about 1-50 mg/ml, and <u>crystallizing the thioredoxin reductase</u> from a solution at a pH of about 6-10 and comprising about 0-40 weight% dimethyl sulfoxide (DMSO) and about 100 mM-6 M sodium formate.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a molecule or molecular complex (I) comprising at least a portion of an S.aureus thioredoxin reductase or thioredoxin reductase-like FAD binding site, where the FAD binding site comprises the amino acids such as Ile 12 or Gly 13 defined in the specification, and is defined by a set of points having a root mean square deviation of less than about 1.1 Angstrom from points representing the backbone atoms of the amino acids as represented by the structure coordinates defined in the specification;
- (2) a molecule or molecular complex (II) comprising at least a portion of an S.aureus thioredoxin reductase or thioredoxin reductase-like NADPH binding site, where the NADPH binding site comprises Cys 135, Cys 138, and the amino acids such as Asn 52 or Ala 136 defined in the specification, and is defined by a set of points having a root mean square deviation of less than about 0.8 Angstrom from points representing the backbone atoms of the amino acids as represented by the structure coordinates defined in the specification;
- (3) a molecule or molecular complex (III) that is structurally homologous to an S.aureus thioredoxin reductase molecule or molecular complex, where the molecule or molecular complex is represented by at least a portion of the structure coordinates defined in the specification;
- (4) a scalable three dimensional configuration of points (IV), where at least a portion of the points or substantially all of the points are derived from structure coordinates of at least a portion of an S.aureus thioredoxin reductase molecule or molecular complex defined in the specification and comprises at least one of a thioredoxin reductase or thioredoxin reductase-like FAD binding site or an NADPH binding site;
- (5) a machine-readable data storage medium (V) comprising a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using the data, is capable of displaying a graphical three-

Record List Display Page 4 of 5

dimensional representation of at least one molecule or molecular complex selected from (I), (II) or (III);

- (6) a machine-readable data storage medium (VI) comprising a data storage material encoded with a first set of machine readable data which, when combined with a second set of machine readable data, using a machine programmed with instructions for using the first set of data and the second set of data, can determine at least a portion of the structure coordinates corresponding to the second set of machine readable data, where the first set of data comprises a Fourier transform of at least a portion of the structural coordinates for S.aureus thioredoxin reductase defined in the specification, and the second set of data comprises an X-ray diffraction pattern of a molecule or molecular complex of unknown structure;
- (7) obtaining (M2) structural information about a molecule or a molecular complex of unknown structure involves <u>crystallizing</u> the molecule or molecular complex, generating an X-ray diffraction pattern from the <u>crystallized</u> molecule or molecular complex, and applying at least a portion of the structure coordinates defined in the specification to the X-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex whose structure is unknown;
- (8) homology modeling (M3) an S.aureus thioredoxin reductase homolog involves aligning the amino acid sequence S.aureus thioredoxin reductase homolog with an amino acid sequence S.aureus thioredoxin reductase and incorporating the sequence of the S.aureus thioredoxin reductase homolog into a model of S.aureus thioredoxin reductase derived from structure coordinates defined in the specification to yield a preliminary model of the S.aureus thioredoxin reductase homolog, subjecting the preliminary model to energy minimization to yield an energy minimized model, and remodeling regions of the energy minimized model where stereochemistry restraints are violated to yield a final model of the S.aureus thioredoxin reductase homolog;
- (9) a computer-assisted method (M4) for identifying an inhibitor of S.aureus thioredoxin reductase activity involves supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, where the molecule or molecular complex comprises at least a portion of an S.aureus thioredoxin reductase or thioredoxin reductase-like FAD or NADPH binding site, supplying the computer modeling application with a set of structure coordinates of a chemical entity, and determining whether the chemical entity is an inhibitor expected to bind to or interface with the molecule or molecular complex, where binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of S.aureus thioredoxin reductase activity;
- (10) making (M5) an inhibitor of S.aureus thioredoxin reductase activity, involves chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of S.aureus thioredoxin reductase activity, where the chemical entity has been identified during M4;
- (11) an inhibitor (VII) of S.aureus thioredoxin reductase activity identified, designed or made by M4 or 'M5;
- (12) a composition (VIII) comprising (VII) or its salt; and
- (13) a crystal (IX) of S.aureus thioredoxin reductase.

ACTIVITY - None given.

MECHANISM OF ACTION - Inhibitor of S.aureus thioredoxin reductase activity (claimed). No supporting data is given.

USE - M1 is useful for crystallizing a S.aureus thioredoxin reductase molecule or

Record List Display Page 5 of 5

molecular complex (claimed). The <u>crystal</u> obtained by M1 is useful for solving the structure of other molecules or molecular complexes, and designing inhibitors of S.aureus thioredoxin reductase. (VIII) is useful for preventing and treating S.aureus thioredoxin reductase mediated disease.

Full Title Citation Fro	nt Review Classification	Date Reference		Claims	KOMC Draw (
Clear Generate	Collection Print	Fwd Refs	Bkwd Re	els Gene	rate OACS
Terms				Documents	
	luctase same aureus a				3

Display Format: - Change Format

<u>Previous Page</u> <u>Next Page</u> <u>Go to Doc#</u>

Record List Display Page 1 of 4

Hit List

Clear Generate Collection Print Fwd Refs Bkwd Refs
Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

1. Document ID: US 20040006218 A1

L3: Entry 1 of 6 File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040006218

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040006218 A1

TITLE: Chlamydia pneumoniae polynucleotides and uses thereof

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 Griffais, Remy Montrouge NY FR Hoiseth, Susan K. Fairport NY US Zagursky, Robert John Victor NY US Metcalf, Benjamin J. Rochester NY US Peek, Joel A. Pittsford NY US Sankaran, Banumathi Penfield NY US Fletcher, Leah Diane Geneseo US

US-CL-CURRENT: 536/23.1

Full Title Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Kosic	Drawa Dr

2. Document ID: US 20030211511 A1

L3: Entry 2 of 6

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211511

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211511 A1

TITLE: Nucleic acids and proteins with thioredoxin reductase activity

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Briggs, Steven P. Del Mar CA US Dalmia, Bipin K. San Diego CA US

Record List Display Page 2 of 4

del Val, Greg	Encinitas	CA	US
Desjarlais, John R.	Pasadena	CA	US
Heifetz, Peter	San Diego	CA	US
Luginbuhl, Peter	San Diego	CA	US
Muchhal, Umesh	Monrovia	CA	US

US-CL-CURRENT: 435/6

Full	Title	Citation	Frent	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC DI	stat De

3. Document ID: US 20030167524 A1

L3: Entry 3 of 6 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030167524

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030167524 A1

TITLE: Methods for the production of multimeric protein complexes, and related

compositions

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

CITY	STATE	COUNTRY	RULE-47
Alberta	CA	CA	
Alberta	CA ,	CA	
San Diego	CA	US	
Del Mar	CA	US	
San Diego		US	
San Diego		US	
	Alberta Alberta San Diego Del Mar San Diego	Alberta CA Alberta CA San Diego CA Del Mar CA San Diego	Alberta CA CA Alberta CA CA San Diego CA US Del Mar CA US San Diego US

US-CL-CURRENT: 800/281; 435/419

Full Title Citat	on Front	Review	Classification	Date	Reference	Attachments	KWIC	Drama De

4. Document ID: US 20030166843 A1

L3: Entry 4 of 6 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166843

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166843 A1

TITLE: Crystallization and structure determination of staphylococcus aureus

thioredoxin reductase

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

Record List Display Page 3 of 4

NAME

CITY

STATE COUNTRY

RULE-47

Benson, Timothy E.

Kalamazoo

MI

US

US-CL-CURRENT: 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNNIC	Drawe D
								•				

5. Document ID: US 20030100743 A1

L3: Entry 5 of 6

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100743

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030100743 A1

TITLE: Nucleic acids and proteins with thioredoxin reductase activity

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dalmia, Bipin K.	San Diego	CA	US	
Briggs, Steven P.	Del Mar	CA	US	
Val, Greg del	Encinitas	CA	US	
Desjarlais, John R.	Pasadena	CA	US	
Heifetz, Peter	San Diego	CA	US	
Luginbuhl, Peter	San Diego	CA	US	
Muchhal, Umesh	West Covina	CA	US	

US-CL-CURRENT: 536/23.1; 435/4, 530/300

Full Title Citation Front Review	Classification Date Reference Sequences A	ttachments Claims KWWC Draw De
······································		
6. Document ID: US 200	020120116 A1	
L3: Entry 6 of 6	File: PGPB	Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020120116

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020120116 A1

TITLE: ENTEROCOCCUS FAECALIS POLYNUCLEOTIDES AND POLYPEPTIDES

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

KUNSCH, CHARLES A. ATLANTA GA US DILLON, PATRICK J. CARLSBAD CA US BARASH, STEVEN

ROCKVILLE

MD

US

 $\text{US-CL-CURRENT: } \underline{536/23.2}; \ \underline{435/252.3}, \ \underline{435/320.1}, \ \underline{435/69.1}, \ \underline{435/70.1}, \ \underline{435/71.1},$ 530/350, 530/387.9, 800/13

Full	Title Citation	Front	Review	Classification	Date	Reference	Sequences	Attachmar	nts Claims	KWIC	Drawn De
Clear	Genera			Print	9 38 - 300000000000000000000000000000000000	wd Refs	Bkwd	Refs	Genera		ACS
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Terms							Do	cuments		
	thioredoxin reductase same aureus and crystal\$9									6	

Display Format: -

Change Format

Previous Page

Next Page

Go to Doc#